Drugs / mRNA-1073
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05375838 | May → Dec 2022 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1073 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05375838 ↗ |
| Modality | Messenger RNA (mRNA) | “The first-generation, mRNA-based, multicomponent mRNA-1073 vaccine” PMID 41627968 ↗ Feb 2026 |
| Route | Intramuscular | “Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.” NCT05375838 ↗ |